Kidney News and Research

RSS

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.

22 Nov 2010

Inexpensive intervention helps patients with hypertension-associated kidney disease

In patients with kidney disease, the Western diet produces an acidic environment in the body that has numerous negative effects and worsens with age as kidney function declines.

21 Nov 2010

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.

21 Nov 2010

Presence of albumin in urine predicts cognitive decline: Study

A new study has found that low amounts of albumin in the urine, at levels not traditionally considered clinically significant, strongly predict faster cognitive decline in older women.

21 Nov 2010

Scientologists target Aborigines with “drug bombs”

The Northern Territory (NT) Health Department of Australia last Saturday warned the Church of Scientology that its drug detoxification therapy, being promoted to Aborigines in Australia by the church was dangerous for people with kidney problems.

21 Nov 2010

Nephrologist’s care reduces ESRD development during first year of dialysis: Study

Among kidney disease patients, earlier care from a nephrologist is associated with a decreased likelihood of developing end-stage renal disease and a lower risk of death during the first year of dialysis, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

20 Nov 2010

Potassium citrate effective for prevention and treatment of osteoporosis: Study

The Western diet creates an acidic environment in the body that removes calcium from bones and may contribute to the development of osteoporosis. Healthy adults who consume the standard US diet sustain a chronic, low-grade state of acidosis that worsens with age as kidney function declines, limiting urinary acid excretion. Reto Krapf, MD (University of Basel, in Bruderholz/Basel, Switzerland) and colleagues designed a study to see if daily alkali as potassium citrate supplement tablets might neutralize these effects.

20 Nov 2010

Early nephrology care associated with lower mortality and incidence of end stage renal disease

Earlier care from a nephrologist reduces the chance of kidney patients developing end-stage renal disease and lowers their risk of death during the first year of dialysis, according to a study by the University of Michigan Kidney Epidemiology & Cost Center.

20 Nov 2010

Abnormal levels of circulating auto-antibodies found in blood of COPD patients

Moderate to severe chronic obstructive pulmonary disease (COPD) may be an auto-immunity problem, according to researchers in Spain, who studied the presence of auto-antibodies in patients with COPD and compared them to levels of control subjects. They found that a significant number of patients with COPD had significant levels of auto-antibodies circulating in their blood, about 5 to 10 times the level in controls.

20 Nov 2010

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that the Company will present new data at the American Society of Nephrology meeting being held in Denver, Colorado, on its late-stage investigational drug Soluble Ferric Pyrophosphate, which is being studied for the treatment of iron-deficiency anemia in ESRD patients.

20 Nov 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Xanodyne Pharmaceuticals Inc. which makes Darvon and Darvocet, the brand version of the prescription pain medication propoxyphene, has agreed to withdraw the medication from the U.S. market at the request of the U.S. Food and Drug Administration. The FDA has also informed the generic manufacturers of propoxyphene-containing products of Xanodyne's decision and requested that they voluntarily remove their products as well.

20 Nov 2010

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

19 Nov 2010

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.

19 Nov 2010

Research suggests new therapeutic approach to prevent transplant rejection

UCLA researchers have pinpointed the culprit behind chronic rejection of heart, lung and kidney transplants. Published in the Nov. 23 edition of Science Signaling, their findings suggest new therapeutic approaches for preventing transplant rejection and sabotaging cancer growth.

19 Nov 2010

Illness perception related to concurrent depression symptoms: Research

New research findings which highlight the detrimental effect of depression on patients with end-stage kidney disease has celebrated at the University of Hertfordshire 2010 Awards Ceremonies yesterday (17 November 2010) at the Cathedral and Abbey Church of St Alban.

19 Nov 2010

African Americans have faster rates of decline in kidney function

African Americans along with some groups of Hispanics have faster rates of decline in kidney function compared to white Americans, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

19 Nov 2010

DCR to present data on DaVita Cathaway program at ASN Annual Meeting

DaVita Clinical Research, a provider of clinical research and diagnostic laboratory services, announced today that 56 posters and five oral presentations will be presented by the Company's unsurpassed renal experts at the 43rd American Society of Nephrology (ASN) Annual Meeting and Scientific Exposition from November 16 - 21, 2010, at the Colorado Convention Center located in Denver, Colorado.

19 Nov 2010

Study suggests pomegranate juice can ward-off complications in kidney disease patients

Studies in recent years have claimed multiple health benefits of pomegranate juice, including that it is a good source of antioxidants and lowers both cholesterol and blood pressure, especially in diabetic and hypertensive patients.

19 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

Kidney News and Research

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Inexpensive intervention helps patients with hypertension-associated kidney disease

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Presence of albumin in urine predicts cognitive decline: Study

Scientologists target Aborigines with “drug bombs”

Nephrologist’s care reduces ESRD development during first year of dialysis: Study

Potassium citrate effective for prevention and treatment of osteoporosis: Study

Early nephrology care associated with lower mortality and incidence of end stage renal disease

Abnormal levels of circulating auto-antibodies found in blood of COPD patients

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

Research suggests new therapeutic approach to prevent transplant rejection

Illness perception related to concurrent depression symptoms: Research

African Americans have faster rates of decline in kidney function

DCR to present data on DaVita Cathaway program at ASN Annual Meeting

Study suggests pomegranate juice can ward-off complications in kidney disease patients

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News